{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:16:37Z","timestamp":1793945797475,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M731448"],"award-info":[{"award-number":["2023M731448"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFA0112300"],"award-info":[{"award-number":["2020YFA0112300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Science and Technology Department of Yunnan Province","doi-asserted-by":"publisher","award":["202302AA310046"],"award-info":[{"award-number":["202302AA310046"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Science and Technology Department of Yunnan Province","doi-asserted-by":"publisher","award":["202101AS070050"],"award-info":[{"award-number":["202101AS070050"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Science and Technology Department of Yunnan Province","doi-asserted-by":"publisher","award":["YSZJGZZ-2020025"],"award-info":[{"award-number":["YSZJGZZ-2020025"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202888"],"award-info":[{"award-number":["82202888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U2102203"],"award-info":[{"award-number":["U2102203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830087"],"award-info":[{"award-number":["81830087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010877","name":"Science, Technology and Innovation Commission of Shenzhen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Department of Science and Technology of Guangdong Province","doi-asserted-by":"publisher","award":["RCYX20221008092911040"],"award-info":[{"award-number":["RCYX20221008092911040"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Department of Science and Technology of Guangdong Province","doi-asserted-by":"publisher","award":["JCYJ20210324103603011"],"award-info":[{"award-number":["JCYJ20210324103603011"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515220051"],"award-info":[{"award-number":["2022A1515220051"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.biopha.2024.116972","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T22:41:44Z","timestamp":1718923304000},"page":"116972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["CDK9 targeting PROTAC L055 inhibits ER\u03b1-positive breast cancer"],"prefix":"10.1016","volume":"177","author":[{"given":"Wenmin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-3516","authenticated-orcid":false,"given":"Ceshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2024.116972_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2024.116972_bib2","first-page":"1","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J. Natl. Cancer Cent."},{"issue":"6","key":"10.1016\/j.biopha.2024.116972_bib3","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2024.116972_bib4","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","article-title":"The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116972_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"4","key":"10.1016\/j.biopha.2024.116972_bib6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"issue":"10286","key":"10.1016\/j.biopha.2024.116972_bib7","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2024.116972_bib8","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.2967\/jnumed.115.157834","article-title":"Clinical diagnosis and management of breast cancer","volume":"57 Suppl 1","author":"McDonald","year":"2016","journal-title":"J. Nucl. Med"},{"issue":"1","key":"10.1016\/j.biopha.2024.116972_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-022-01535-7","article-title":"Clinical considerations for the design of PROTACs in cancer","volume":"21","author":"Nieto-Jimenez","year":"2022","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2024.116972_bib10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.116972_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.biopha.2024.116972_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2024.116972_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678559","article-title":"CDK9: a comprehensive review of its biology, and its role as a potential target for anti-cancer agents","volume":"11","author":"Anshabo","year":"2021","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116972_bib14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.apsb.2021.10.024","article-title":"Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer","volume":"12","author":"Cheng","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.biopha.2024.116972_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105476","article-title":"Antitumoral activity of a CDK9 PROTAC compound in HER2-positive breast cancer","volume":"23","author":"Noblejas-Lopez","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.biopha.2024.116972_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143418","article-title":"Phosphorylation of OGFOD1 by cell cycle-dependent kinase 7\/9 enhances the transcriptional activity of RNA polymerase II in breast cancer cells","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116972_bib17","article-title":"CDK9 inhibitor induces the apoptosis of B-cell acute lymphocytic leukemia by inhibiting c-Myc-mediated glycolytic metabolism","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116972_bib18","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1535-7163.MCT-18-1023","article-title":"Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma","volume":"18","author":"Hashiguchi","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"19","key":"10.1016\/j.biopha.2024.116972_bib19","doi-asserted-by":"crossref","first-page":"14822","DOI":"10.1021\/acs.jmedchem.1c01350","article-title":"Discovery of potent and selective CDK9 degraders for targeting transcription regulation in triple-negative breast cancer","volume":"64","author":"Wei","year":"2021","journal-title":"J. Med Chem."},{"issue":"16 Suppl","key":"10.1016\/j.biopha.2024.116972_bib20","first-page":"S356","article-title":"Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway","volume":"24","author":"Lyle","year":"2018","journal-title":"Am. J. Manag Care"},{"issue":"18","key":"10.1016\/j.biopha.2024.116972_bib21","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116972_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2024.116972_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105109","article-title":"PROTACs technology for targeting non-oncoproteins: advances and perspectives","volume":"114","author":"Wang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2024.116972_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcell.2015.00016","article-title":"Targeting cell cycle regulators in hematologic malignancies","volume":"3","author":"Aleem","year":"2015","journal-title":"Front Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116972_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2024.116972_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.tips.2008.03.003","article-title":"Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology","volume":"29","author":"Wang","year":"2008","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.biopha.2024.116972_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.molimm.2021.05.004","article-title":"Functionally active cyclin-dependent kinase 9 is essential for porcine reproductive and respiratory syndrome virus subgenomic RNA synthesis","volume":"135","author":"Wang","year":"2021","journal-title":"Mol. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116972_bib28","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2015.5805","article-title":"Postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer: a review","volume":"2","author":"Speers","year":"2016","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116972_bib29","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.gendis.2021.06.005","article-title":"Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells","volume":"9","author":"Cheng","year":"2022","journal-title":"Genes Dis."},{"issue":"7","key":"10.1016\/j.biopha.2024.116972_bib30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.clon.2012.05.003","article-title":"Intensity-modulated radiotherapy in the treatment of breast cancer","volume":"24","author":"Dayes","year":"2012","journal-title":"Clin. Oncol. (R. Coll. Radio. )"},{"issue":"1","key":"10.1016\/j.biopha.2024.116972_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2219470","article-title":"Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments","volume":"24","author":"Xiao","year":"2023","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2024.116972_bib32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","article-title":"First-in-human dose-escalation study of cyclin-dependent kinase 9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy","volume":"28","author":"Diamond","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"54","key":"10.1016\/j.biopha.2024.116972_bib33","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.biopha.2024.116972_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113091","article-title":"Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion","volume":"211","author":"Qiu","year":"2021","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2024.116972_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bioorg.2018.08.028","article-title":"Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity","volume":"81","author":"Bian","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2024.116972_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2024.116972_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111952","article-title":"Development of selective mono or dual PROTAC degrader probe of CDK isoforms","volume":"187","author":"Zhou","year":"2020","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2024.116972_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115342","article-title":"Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation","volume":"254","author":"Tokarski","year":"2023","journal-title":"Eur. J. Med Chem."},{"issue":"1","key":"10.1016\/j.biopha.2024.116972_bib39","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","article-title":"Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"26","author":"Portman","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2024.116972_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharm. Ther."},{"issue":"18","key":"10.1016\/j.biopha.2024.116972_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186479","article-title":"Targeting cell cycle in breast cancer: CDK4\/6 inhibitors","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2024.116972_bib42","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: A review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int J. Cancer"},{"issue":"13","key":"10.1016\/j.biopha.2024.116972_bib43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/1538-7445.AM2021-44","article-title":"The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116972_bib44","doi-asserted-by":"crossref","unstructured":"Zhang, H. et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell, 175, 1244\u20131258. \u3008https:\/\/doi.org\/10.1016\/j.cell.2018.09.051\u3009.","DOI":"10.1016\/j.cell.2018.09.051"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224008564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224008564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:01:59Z","timestamp":1782172919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224008564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":44,"alternative-id":["S0753332224008564"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116972","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK9 targeting PROTAC L055 inhibits ER\u03b1-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116972"}}